The Central Nervous System International Prognostic Index (CNS-IPI) is a clinical calculator used in the field of oncology, specifically for patients with diffuse large B-cell lymphoma. This scoring system is used to predict the risk of central nervous system relapse in patients with DLBCL. The CNS-IPI takes into account several factors including age, performance status, lactate dehydrogenase levels, stage of disease, extranodal sites, and the involvement of specific organs such as the kidney or adrenal gland.
The clinical utility of the CNS-IPI is to aid clinicians in identifying high-risk patients who may benefit from prophylactic CNS-directed therapy. It can also be used to stratify patients in clinical trials.
The CNS-IPI is not applicable to patients with other types of lymphoma or to patients with DLBCL who have already had a CNS relapse. It should also be used with caution in patients with significant comorbidities or those who are not candidates for intensive chemotherapy.
Reference
Norbert Schmitz, Samira Zeynalova, Maike Nickelsen et al. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. J Clin Oncol. 2016 Sep 10;34(26):3150-6.
Open reference URL